Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker ...

Global City Media, and its associated brands will use the lawful basis of legitimate ... to buy a 50% controlling stake in Sanofi’s consumer health unit, Opella. Kirkland is advising CD&R on the M&A ...

Upon completion of the transaction, CD&R would indirectly acquire the right to direct the exercise of 60.40 per cent of the voting rights of Sanofi Consumer Healthcare India and control over it ...

Freshfields is advising Sanofi on corporate and consumer healthcare aspects of the deal, which is valued at around €16 billion ($17.28 billion). Sanofi would maintain a 48% stake in Opella.